Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
TCNNF Quote, Financials, Valuation and Earnings
Last price:
$7.96
Seasonality move
:
23.55%
Day range:
$7.84 - $8.17
52-week range:
$3.02 - $11.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.30x
P/B ratio:
1.29x
Volume:
185.8K
Avg. volume:
1.4M
1-year change:
67.96%
Market cap:
$1.5B
Revenue:
$1.2B
EPS (TTM):
-$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$287.5M | -$0.08 | -1.21% | -90.79% | $21.00 |
|
ARVN
Arvinas, Inc.
|
$27.6M | -$0.74 | -37.06% | -11.21% | $12.44 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TLRY
Tilray Brands, Inc.
|
$211.1M | -- | 8.34% | -100% | $16.17 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$8.10 | $21.00 | $1.5B | -- | $0.00 | 0% | 1.30x |
|
ARVN
Arvinas, Inc.
|
$12.17 | $12.44 | $781.6M | -- | $0.00 | 0% | 2.84x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TLRY
Tilray Brands, Inc.
|
$10.15 | $16.17 | $1.2B | -- | $0.00 | 0% | 3.54x |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
40.31% | 0.421 | 53.38% | 3.72x |
|
ARVN
Arvinas, Inc.
|
1.66% | 2.758 | 1.57% | 5.58x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TLRY
Tilray Brands, Inc.
|
17.36% | 2.619 | 21.25% | 1.39x |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TCNNF
Trulieve Cannabis Corp.
|
$140.4M | $45.2M | -6.43% | -10.71% | 15.69% | $60.8M |
|
ARVN
Arvinas, Inc.
|
$40.6M | -$44M | -9.68% | -9.81% | -105.01% | -$59.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TLRY
Tilray Brands, Inc.
|
$53.5M | -$10.9M | -74.45% | -84.8% | -5.19% | -$10.9M |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Trulieve Cannabis Corp. vs. Competitors
-
Which has Higher Returns TCNNF or ARVN?
Arvinas, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of -83.77%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Arvinas, Inc.'s return on equity of -9.81%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B ARVNArvinas, Inc.96.9% -$0.48 $573.9M -
What do Analysts Say About TCNNF or ARVN?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 159.26%. On the other hand Arvinas, Inc. has an analysts' consensus of $12.44 which suggests that it could grow by 2.2%. Given that Trulieve Cannabis Corp. has higher upside potential than Arvinas, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than Arvinas, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.8 0 0 ARVNArvinas, Inc.7 9 1 -
Is TCNNF or ARVN More Risky?
Trulieve Cannabis Corp. has a beta of 1.154, which suggesting that the stock is 15.401% more volatile than S&P 500. In comparison Arvinas, Inc. has a beta of 2.446, suggesting its more volatile than the S&P 500 by 144.578%.
-
Which is a Better Dividend Stock TCNNF or ARVN?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Arvinas, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or ARVN?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Arvinas, Inc. quarterly revenues of $41.9M. Trulieve Cannabis Corp.'s net income of -$23.7M is higher than Arvinas, Inc.'s net income of -$35.1M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Arvinas, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.30x versus 2.84x for Arvinas, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.30x -- $288.2M -$23.7M ARVNArvinas, Inc.2.84x -- $41.9M -$35.1M
-
Which has Higher Returns TCNNF or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of -255.85%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TCNNF or NBY?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 159.26%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Trulieve Cannabis Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.8 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TCNNF or NBY More Risky?
Trulieve Cannabis Corp. has a beta of 1.154, which suggesting that the stock is 15.401% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock TCNNF or NBY?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or NBY?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Trulieve Cannabis Corp.'s net income of -$23.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.30x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.30x -- $288.2M -$23.7M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns TCNNF or PTN?
Palatin Technologies has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of --. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B PTNPalatin Technologies-- -- -- -
What do Analysts Say About TCNNF or PTN?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 159.26%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Trulieve Cannabis Corp., analysts believe Palatin Technologies is more attractive than Trulieve Cannabis Corp..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.8 0 0 PTNPalatin Technologies0 0 0 -
Is TCNNF or PTN More Risky?
Trulieve Cannabis Corp. has a beta of 1.154, which suggesting that the stock is 15.401% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TCNNF or PTN?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or PTN?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Palatin Technologies quarterly revenues of --. Trulieve Cannabis Corp.'s net income of -$23.7M is higher than Palatin Technologies's net income of --. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.30x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.30x -- $288.2M -$23.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns TCNNF or TLRY?
Tilray Brands, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of 0.72%. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Tilray Brands, Inc.'s return on equity of -84.8%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B TLRYTilray Brands, Inc.25.56% -$0.00 $1.8B -
What do Analysts Say About TCNNF or TLRY?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 159.26%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $16.17 which suggests that it could grow by 59.28%. Given that Trulieve Cannabis Corp. has higher upside potential than Tilray Brands, Inc., analysts believe Trulieve Cannabis Corp. is more attractive than Tilray Brands, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.8 0 0 TLRYTilray Brands, Inc.2 6 0 -
Is TCNNF or TLRY More Risky?
Trulieve Cannabis Corp. has a beta of 1.154, which suggesting that the stock is 15.401% more volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.794%.
-
Which is a Better Dividend Stock TCNNF or TLRY?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or TLRY?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Tilray Brands, Inc. quarterly revenues of $209.5M. Trulieve Cannabis Corp.'s net income of -$23.7M is lower than Tilray Brands, Inc.'s net income of $1.5M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.30x versus 3.54x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.30x -- $288.2M -$23.7M TLRYTilray Brands, Inc.3.54x -- $209.5M $1.5M
-
Which has Higher Returns TCNNF or TOVX?
Theriva Biologics, Inc. has a net margin of -8.24% compared to Trulieve Cannabis Corp.'s net margin of --. Trulieve Cannabis Corp.'s return on equity of -10.71% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TCNNFTrulieve Cannabis Corp.48.72% -$0.14 $2B TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About TCNNF or TOVX?
Trulieve Cannabis Corp. has a consensus price target of $21.00, signalling upside risk potential of 159.26%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Trulieve Cannabis Corp., analysts believe Theriva Biologics, Inc. is more attractive than Trulieve Cannabis Corp..
Company Buy Ratings Hold Ratings Sell Ratings TCNNFTrulieve Cannabis Corp.8 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is TCNNF or TOVX More Risky?
Trulieve Cannabis Corp. has a beta of 1.154, which suggesting that the stock is 15.401% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock TCNNF or TOVX?
Trulieve Cannabis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trulieve Cannabis Corp. pays 0.7% of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend. Trulieve Cannabis Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TCNNF or TOVX?
Trulieve Cannabis Corp. quarterly revenues are $288.2M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Trulieve Cannabis Corp.'s net income of -$23.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Trulieve Cannabis Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trulieve Cannabis Corp. is 1.30x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TCNNFTrulieve Cannabis Corp.1.30x -- $288.2M -$23.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 0.62% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 2.27% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 7.93% over the past day.
